eagi restriction enzyme  (New England Biolabs)


Bioz Verified Symbol New England Biolabs is a verified supplier
Bioz Manufacturer Symbol New England Biolabs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    New England Biolabs eagi restriction enzyme
    CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An <t>EagI</t> restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested <t>PCR</t> product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size
    Eagi Restriction Enzyme, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eagi restriction enzyme/product/New England Biolabs
    Average 86 stars, based on 4 article reviews
    Price from $9.99 to $1999.99
    eagi restriction enzyme - by Bioz Stars, 2022-08
    86/100 stars

    Images

    1) Product Images from "Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts, et al. Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts"

    Article Title: Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts, et al. Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts

    Journal: Aging Cell

    doi: 10.1111/acel.13010

    CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An EagI restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested PCR product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size
    Figure Legend Snippet: CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An EagI restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested PCR product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size

    Techniques Used: Expressing, Mutagenesis, Amplification, Polymerase Chain Reaction

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    New England Biolabs eagi restriction enzyme
    CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An <t>EagI</t> restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested <t>PCR</t> product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size
    Eagi Restriction Enzyme, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eagi restriction enzyme/product/New England Biolabs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eagi restriction enzyme - by Bioz Stars, 2022-08
    86/100 stars
      Buy from Supplier

    93
    New England Biolabs eagi restriction enzymes
    CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An <t>EagI</t> restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested <t>PCR</t> product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size
    Eagi Restriction Enzymes, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eagi restriction enzymes/product/New England Biolabs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eagi restriction enzymes - by Bioz Stars, 2022-08
    93/100 stars
      Buy from Supplier

    86
    New England Biolabs nhei eagi restriction enzymes
    CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An <t>EagI</t> restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested <t>PCR</t> product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size
    Nhei Eagi Restriction Enzymes, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nhei eagi restriction enzymes/product/New England Biolabs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    nhei eagi restriction enzymes - by Bioz Stars, 2022-08
    86/100 stars
      Buy from Supplier

    Image Search Results


    CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An EagI restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested PCR product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size

    Journal: Aging Cell

    Article Title: Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts, et al. Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts

    doi: 10.1111/acel.13010

    Figure Lengend Snippet: CDKN2A gene and its expression in the presence or absence of the c.53C > T mutation. (a) Schematic representation of the genomic structure and transcripts of the CDKN2A gene locus with c.53C > T mutation and primer locations. The exons are shown as rectangles and primers as arrows. Primers 1 and 5 were used for RFLP analysis (see figure c), primers 3 and 4 were used for ddPCR analysis (see figure b), and primers 2 and 5 were used for additional ddPCR analysis (see Figure S1 ). An EagI restriction site is present in a wild‐type carrier, but absent in the individual with the c.53C > T mutation. The size of the locus, transcripts, exons, and introns is not shown to scale. Of note, the size of the intron between exon 1a and exon 2 is approximately 3.5 kb. (b) Comparison of CDKN2A transcript copies after normalization to GAPDH in early and late passage primary fibroblasts from young and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from the XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage. Primers 3 and 4 were used for this ddPCR analysis. (c) RFLP analysis of CDKN2A transcript in early and late passage primary fibroblasts from young age healthy and advanced age healthy subjects without the c.53C > T mutation and in early and late passage primary fibroblasts from XPA patient where the c.53C > T mutation is present at an allele frequency of 55.3% in the late passage only. Primers 1 and 5 were first used to amplify the cDNA followed by digestion with restriction enzyme EagI (indicated by +). Part of the amplified sample was used as an undigested control (indicated by −). Undigested PCR product is 658 bp in size, while digested fragments are 274 bp and 384 bp in size

    Article Snippet: After clean‐up with QIAquick PCR purification kit (Qiagen) according to the manufacturer's recommendations, 25% of the PCR product was digested using EagI restriction enzyme (10 U/reaction; New England Biolabs) and visualized on 2% agarose gel.

    Techniques: Expressing, Mutagenesis, Amplification, Polymerase Chain Reaction